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Venous ulceration is a serious health-care prob-
lem in western countries. In the United Kingdom
alone 150,000 to 200,000 patients receive treat-
ment at any one time from an estimated population
at risk for ulceration of 1 to 2 million.1-3 The cost of
this problem is massive. Each ulcer requires frequent
dressing changes, and community nurses spend 10%
to 30% of their time attending to this problem. It is
estimated that the Health Service in the United
Kingdom spends £600 million per annum4 on man-
agement of this problem,4 which amounts to nearly
2% of the total health-care expenditure.
Among volunteers without venous disease,
leukocyte sequestration in the lower limb and white
blood cell activation have been produced by means
of experimental venous hypertension lasting 30
minutes.5 At the same time various endothelial fac-
tors are released, suggesting that this stimulus is
enough to produce minor endothelial injury.
Among patients with venous disease, plasma levels
of neutrophil elastase and lactoferrin (a secondary
granule enzyme) also are elevated, confirming the
presence of a chronic inflammatory state.6
However, there does not seem to be a great differ-
ence between the extent of this inflammatory
response among patients with uncomplicated vari-
cose veins and the extent among patients trophic
skin changes. Many other factors are clearly
involved. Inflammatory mechanisms play an impor-
tant role in the pathogenesis of venous disease, but
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Skin damage in the presence of chronic venous disease is partially mediated through
leukocytes. The endothelium is activated and exhibits proliferation in the skin. Up-reg-
ulation of vascular endothelial growth factor (VEGF) expression in the skin of patients
with chronic venous disease has been demonstrated with immunohistologic techniques.
Abnormal VEGF expression can have local deleterious effects. The aim of this study was
to determine whether patients with chronic venous disease have elevated plasma levels of
VEGF.
We conducted a prospective study with 30 patients with varicose veins of clinical, etio-
logic, anatomic, and pathologic class C3 (normal skin, n = 15) and C4 (trophic skin
changes, n = 15) and 25 control subjects with no clinical evidence of venous or arterial
disease of the lower limb. Blood samples were collected from a foot vein of each subject
before and after a period of experimental venous hypertension produced by means of
standing. Assay of VEGF protein was performed with a sandwich enzyme-linked
immunosorbent assay.
Plasma VEGF level was elevated in both groups of patients with venous disease com-
pared with the control group. The median VEGF levels among patients were 81 pg/mL
(interquartile range [IQR] 56 to 122) supine and 98 pg/mL (IQR 63 to 153) after
standing for 30 minutes. Median VEGF levels among control subjects were 52 pg/mL
(IQR 35 to 71) lying supine and 60 pg/mL (IQR 39 to 105) after standing for 30 min-
utes. Experimental venous hypertension caused a small rise in VEGF levels among the
patients but not the control subjects. Further studies are required to determine whether
increased VEGF expression contributes to tissue injury in chronic venous disease. (J Vasc
Surg 1998;28:535-40.)
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the exact mechanisms producing lipodermatosclero-
sis and venous ulceration remain to be elucidated.5
Skin damage caused by chronic venous insuffi-
ciency is associated with severe microangiopathic
changes in the skin. This was first recognized histo-
logically by Burnand et al.7 Normal skin has occa-
sional capillaries on histologic sections, and the num-
ber of capillaries does not increase among patients
with varicose veins. However, in the presence of lipo-
dermatosclerosis, there is great proliferation of the
skin capillaries. Microscopic examination of the capil-
laries has been used to study the microcirculation of
the skin in the presence of venous disease.8 This has
shown that the capillaries are elongated and tortuous.
In advanced stages they look glomerular compared
with the pin-shaped capillary loops normally found.9
There appears to be an increase in the amount of cap-
illary endothelium but not in the number of capillar-
ies. The highly tortuous capillaries are cut many times
on histologic sections, and this accounts for the appar-
ent increase in numbers reported by Burnand et al.7
The resulting microcirculation is abnormal and shows
many features of impaired efficiency, including a
diminished cutaneous hyperemic response.10 The
proliferation of the capillary endothelium has not
been fully explained, although production of vascular
endothelial growth factor (VEGF) in the epidermis
has been demonstrated (H. Pardoe, unpublished data,
1996). A possible explanation of the microangiopath-
ic changes is that VEGF reaches the main capillaries in
the underling papillary dermis and causes them to pro-
liferate. Many growth factors have been identified that
might be responsible for the angiogenic response in
chronic venous disease.11,12 The aim of our study was
to measure plasma VEGF levels among control sub-
jects and patients with chronic venous disease before
and after a period of experimental hypertension to
investigate the role of this angiogenic factor in devel-
opment of chronic venous disease.
METHODS 
Ethical consent to undertake this study was
obtained from the committee for medical ethics at
our institution. Patients attending the vascular clinic
at the Middlesex Hospital for management of lower
limb venous problems were asked to participate.
Twenty-five persons volunteered to act as control
subjects. This group comprised members of the staff
of the department of surgery and patients being
treated for unrelated conditions. They had no symp-
toms or signs of venous disease of the lower limb.
Volunteers with a history or clinical evidence of arte-
rial disease, diabetes mellitus, connective tissue dis-
orders including rheumatoid arthritis, blood disor-
ders, infection within the previous 6 weeks, or use of
medication known to alter white blood cell activity
were excluded from the study. Patients and controls
who gave informed, written consent were consid-
ered for inclusion in this study. The demographic
details on subjects included are shown in Table I. All
subjects were examined clinically for signs of venous
disease by a surgeon trained in the management of
vascular disease. Patients were divided into the two
groups on the basis of clinical, etiologic, anatomic,
and pathologic (CEAP)13 class determined at clini-
cal examination. There were 15 patients in the C3
group (varicose veins and edema) and 15 patients in
the C4 group (trophic skin changes). Patients
underwent color duplex ultrasonography by skilled
vascular technologists and photoplethysmography.
The extent of venous valvular incompetence and
post-thrombotic venous damage in the deep and
superficial venous systems was established and
recorded systematically.
A foot vein or the long saphenous vein at the ankle
was cannulated with an 18-gauge cannula (Vasculon
2; Viggo-Spectramed, Helsingborg, Sweden). Blood
samples were obtained from each subject before and
after a period of experimental venous hypertension.
The subject first lay supine for 20 minutes to mini-
mize venous pressure in the leg. The subject then
stood supported with minimal movement for 30 min-
utes. This was followed by a 10-minute period of
lying supine. Blood was collected at the end of each
period; ethylenediametetraacetic acid (EDTA) was
used as the anticoagulant. Plasma was separated by
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Table I. Distribution of subjects according to sex and clinical, etiologic, anatomic, pathologic (CEAP)
stage
Age (y, mean No. with superficial No. with deep and superficial No. with post-
Stage No. of patients value and range) venous insufficiency venous insufficiency* thrombotic damage
C0 8F, 7M 31 (23-42) — — —
C3 12M, 3F 48 (29-73) 13 2 (2) 1
C4 7F, 8M 51 (32-69) 3 12 (10) 10
*Value in parentheses is number of patients with superficial venous insufficiency.
means of spinning the blood sample at 2000 rpm for
10 minutes. We showed previously that standing pro-
duces pressures of 70 to 80 mm Hg in the foot
veins.14 Because this pressure is generated hydrostati-
cally, it is irrespective of the presence of venous insuf-
ficiency, which would be important if the patients
were exercising during the standing period. It has
long been recognized that abnormalities in venous
pressure among patients with lower limb venous dis-
ease become apparent only during exercise. 
Assay of VEGF165 protein was performed with a
sandwich enzyme-linked immunosorbent assay. A
Quantikine kit supplied by R&D systems (Oxon,
United Kingdom) was used. Plasma levels were read
from standard curves obtained by means of plotting
mean absorbance for standards. The kit used enables
detection of 25% of VEGF protein activity in the
plasma. In contrast, detectable levels in serum are
100%. Thus absolute levels of VEGF165 are about
four times the levels depicted herein. However,
detection in both serum and plasma is equally reli-
able and the manufacturer confirms that this kit is
suitable for use with plasma samples. There are no
reports to indicate significant differences among
healthy persons in the respective age groups.
The test is used to measure levels of VEGF165.
This is one of the four transcripts that encode mature
monomeric VEGF (VEGF121, VEGF165, VEGF189,
and VEGF206). VEGF121 and VEGF165 are diffusible
proteins secreted into the medium. The other two are
mostly bound to heparin-containing proteoglycans in
the matrix. Results obtained for naturally occurring
human VEGF and the recombinant VEGF121 showed
linear curves parallel to the standard curves obtained
with the Quantikine kit standards.
RESULTS
The median plasma VEGF165 levels for controls
and patients before and after induction of venous
hypertension are shown in Table II. There have been
no large population studies of plasma levels of VEGF
measured with this assay. However, data on record
in the supplier’s laboratory show a median plasma
level of 62 pg/mL (R&D Systems) for control sub-
jects, which is very close to that for our control sub-
jects (52 pg/mL lying, 60 pg/mL standing). In our
study, levels of VEGF were higher among patients
than among controls in both supine and standing
positions. Because of the large scatter of the data,
statistical significance was not reached until the
results for all patients with venous disease were con-
sidered together. Levels of VEGF were approxi-
mately 60% higher for the patient groups than for
the control group in both lying and standing posi-
tions (Fig. 1). The two patient groups showed simi-
lar levels of VEGF (Fig. 2). There was a small rise in
VEGF level after 30 minutes of venous hypertension
in the control group, which did not reach statistical
significance. The patient groups had a similar mod-
est rise in plasma VEGF level, which did reach sig-
nificance because of the larger numbers when all
patients were considered together. 
DISCUSSION
VEGF (vascular permeability factor) is a member
of the platelet-derived growth factor (PDGF) family.
It is a disulphide linked homodimeric glycoprotein.
It is a potent mitogen for endothelial cells even at
very low concentrations and markedly increases vas-
cular permeability.15 VEGF is important in both
angiogenesis and edema formation.16 VEGF acts
through two different tyrosine kinase membrane
receptors, which have been identified on vascular
endothelial cells.17 Its angiogenic role in neoplasia is
well established. Cells that produce VEGF include
vascular smooth muscle cells, fibroblasts, ker-
atinocytes, and histiocytes.18 VEGF is ubiquitous in
wound repair, and the inflammatory process has an
important part in the healing process. However,
abnormally increased levels over a prolonged period
can have local deleterious effects.
In chronic venous disease there is proliferation of
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Table II. Median plasma levels of vascular endothelial growth factor (pg/mL)
Study period Control subjects Class C3 patients Class C4 patients All patients
Supine (P = difference between 52 (35-71) 92 (70-108) P = 0.01 82 (47-157) P = 0.072 81 (56-122) P = 0.004
control subjects and patients)*
Standing (P = difference between 60 (39-105) 102 (60-118) P = 0.066 99 (48-200) P = 0.14 98 (63-153) P = 0.03
control subjects and patients)*
P = difference between supine and P = 0.08 P = 0.17 P = 0.19 P = 0.008
standing periods†
Values in parentheses are interquartile range.
*Mann-Whitney test.
†Wilcoxon signed rank test.
vessels in the skin.19 This correlates with the severi-
ty of clinical skin damage. Until recently the growth
factors, which mediate this process, have remained
unknown. It has been reported that VEGF and
platelet-derived growth factor expression is
increased in the skin of patients with venous disease
and may be the cause of vascular proliferation.16
In this study our aim was to assess the association
of the development of skin changes with plasma
VEGF levels. We therefore used the CEAP system to
divide the patients into those with no clinically
detectable skin changes and those with lipoder-
matosclerosis. This allowed us to investigate the fac-
tors responsible for development of the skin
changes, which are not necessarily the factors that
cause venous valvular incompetence of the deep or
superficial veins. It is recognized that physiologic
indices of venous function, such as air plethysmo-
graphic findings, are predictive of the severity of
venous disease but that there is considerable overlap
between the impairment of venous function among
patients from different clinical groups. This simply
reflects the fact that the development of skin
changes and venous ulceration is not simply a matter
of ambulatory venous hypertension–producing leg
ulcers but that the response of the tissues is an
important determinant of the severity of the clinical
syndrome. It is specifically this point that we wanted
to investigate, because it reflects a poorly under-
stood aspect of the disease that might eventually be
a useful target for drug treatment.
Our control subjects were somewhat younger
than either of the study groups. We investigated the
influence of age on VEGF levels among the control
subjects and could find no correlation. A Medline
search of the world literature revealed no studies of
the influence of age on plasma VEGF levels. The
median VEGF levels among our control subjects were
similar to those measured by the manufacturer of the
analysis kit with human control subjects, and we
believe that these levels reflect those in a population
of healthy subjects. Nevertheless we admit that the
age difference between the patient and control groups
leaves the possibility that some of the differences we
observed may be explained with age differences.
VEGF is strongly expressed by epidermal ker-
atinocytes during wound healing, in psoriasis, in skin
with ultraviolet burns, and in bullous diseases such
as erythema multiforme and bullous pemphigoid.
All these disorders are characterized by increased
microvascular permeability and angiogenesis. A large
increase in VEGF messenger ribonucleic acid
(mRNA) and protein levels is seen after irradiation
of quiescent keratinocytes with physiologically rele-
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Fig. 2. Plasma levels of vascular endothelial growth factor
(VEGF). Comparison between patients with and without
skin changes. Horizontal lines at the top compare VEGF
levels in the supine and standing positions between the
two groups. P values indicated by special symbols are
respective values for differences between supine and stand-
ing positions.
Fig. 1. Plasma levels of vascular endothelial growth factor
(VEGF). Comparison between patients and controls.
Horizontal lines at the top compare VEGF levels in the
supine and standing positions between the two groups. P
values indicated by special symbols are respective values
for differences between supine and standing positions
within the same group.
vant doses of ultraviolet B light. Overexpression of
VEGF is considered dependent on de novo protein
synthesis.20 Tissue damage in general, especially
hypoxic damage, can cause up-regulation of VEGF
expression.7,21,22
The data from this study show that both groups
of patients had similar elevations in plasma VEGF
level compared with controls. This may reflect the
fact that this growth factor is induced in patients
with venous disease to repair tissue damage caused
by venous hypertension. However, measurement of
plasma levels may not reliably reflect the actual tissue
levels expressed in the region of tissue repair. It is
unlikely that VEGF as reflected by these plasma lev-
els is an important factor in explaining the differ-
ences between C3 and C4 patients. 
Epidermally derived VEGF is likely to be a factor
in the angiogenesis of lipodermatosclerosis. This
increased expression of VEGF is seen even before any
skin changes develop. We found increased serum lev-
els of VEGF in our study with patients with venous
disease. In our study the changes in serum levels were
actually more prominent among the group with C3
disease. Studies that measure the expression of VEGF
mRNA levels might more conclusively prove the
actual site of origin of the protein.
VEGF seems to act both in the short term (over
a few minutes) and in the long term (over a few
hours) to increase microvascular permeability.23
VEGF promotes extravasation of fibrinogen and
deposition in the tissues as fibrin. This might repre-
sent a mechanism for formation of the fibrin cuffs
characteristically found in chronic venous disease.24
Our previous work showed that leukocyte activa-
tion occurs within 30 minutes of experimental
induction of venous hypertension with the same
model as used in this study. This can be shown for
both control subjects and those with venous disease.
This leukocyte activation is associated with evidence
of endothelial activation, and we believe these are
the mechanisms that initiate the skin damage caused
in chronic venous disease. This may initiate a repair
process that involves increased expression of VEGF
by keratinocytes and vascular smooth muscle cells.
This causes the neovascularization essential to any
tissue repair process. The neovasculature is perme-
able to large molecules compared with normal capil-
lary endothelium and allows perivascular accumula-
tion of large molecules, accounting for the fibrin
cuff originally reported by Burnand et al.7 Such
perivascular cuffs are of course common in many
inflammatory conditions. 
It has been demonstrated that hyaluron oligosac-
charides (OHA) in the intercellular matrix modulate
the invasive and proteolytic properties of bovine
microvascular endothelial cells and synergize specifi-
cally with VEGF in induction of angiogenesis in
vitro. The synergism between OHA and VEGF
probably plays a role in regulation of angiogenesis.
This might be exploited therapeutically in situations
that would benefit from modulation of growth of
new blood vessels.22,25
VEGF has been associated with stimulation of
nitric oxide production. The signaling cascade is
believed to involve inducible nitric oxide synthase,
guanylate cyclase, and cyclic guanosine monophos-
phate–dependent protein kinase. Experimental admin-
istration of VEGF has been found to cause severe
hypotension among animals. The hypotension is
thought to be mediated by production of nitric oxide
and is reversible with appropriate blocking therapy
with N-(G)-monomethyl-L-arginine.21,26 The pres-
ence of nitric oxide also can explain the hyperperme-
ability induced by VEGF. Excessive release of nitric
oxide can be caused by this mechanism. in contrast to
its usual beneficial role, this free radical may contribute
to local tissue damage.
To summarize all these observations, a possible
scenario for the sequence of events in skin injury in
the presence of chronic venous disease is as follows.
Damage to the tissues is caused by abnormal leuko-
cyte activation. The injury itself may cause either an
increase in VEGF protein synthesis or release of
VEGF from depot sites. Activated platelets or
macrophages at the site of injury may release peptide
factors that in turn stimulate VEGF release. The
abundant macrophages in skin exposed to chronic
venous disease also are a potential source of VEGF.
These macrophages can be present within the base-
ment membrane or extracellular matrix. Components
of the extracellular matrix, such as heparan proteo-
glycan, also are exposed by injury. These are known
to facilitate migration and tube formation by
endothelial cells.7,27 Resynthesis of components of
the extracellular matrix and migration of pericytes
might represent a mechanism of quenching the
angiogenic stimulus.28
CONCLUSIONS
In our study plasma VEGF levels were elevated
in both groups of patients with venous disease com-
pared with control subjects. Experimental venous
hypertension caused a further statistically significant
rise in VEGF levels. Increased VEGF expression may
play a role in causing tissue injury in the presence of
chronic venous disease. Leukocyte-mediated tissue
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damage might directly release VEGF from depots in
the intima or intercellular matrix. Excessive neovas-
cularization with hyperpermeable vessels might con-
tribute directly to the skin changes that occur with
chronic venous disease. Increased production of
nitric oxide is a possible mechanism of local tissue
damage. The source of the VEGF detected in this
study is unclear. We are undertaking studies to
determine localization of VEGF mRNA expression
to confirm the origin of the protein. It remains to be
seen whether an early rise in plasma VEGF level will
serve as a marker for development of skin changes.
Although VEGF may well be the cause of cutaneous
capillary proliferation in venous disease, whether
pharmacologic inhibition of this process would
achieve a clinically useful effect is very much a mat-
ter for debate.
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